AJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, H.
Right arrow Articles by Podoloff, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, H.
Right arrow Articles by Podoloff, D. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

CT Evaluation of the Response of Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment: A Quantitative Analysis Correlated with FDG PET Findings

Haesun Choi1, Chuslip Charnsangavej1, Silvana de Castro Faria1, Eric P. Tamm1, Robert S. Benjamin2, Marcella M. Johnson3, Homer A. Macapinlac1 and Donald A. Podoloff1

1 Department of Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.
2 Department of Sarcoma, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030.
3 Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030.



View larger version (21K):

[in a new window]
  		Fig. 1. —Scatterplot shows sizes of 173 lesions in 36 patients during treatment. Change in absolute tumor size was small but statistically significant up to 8 months after treatment (p = 0.0070, linear regression analysis).

 


View larger version (11K):

[in a new window]
  		Fig. 2. —Graph shows change in mean tumor size on CT images in 29 patients. Decrease in mean tumor size measured 2 months after treatment was significant (p = 0.0025, Student's t test; p = 0.0013, Wilcoxon's signed rank test).

 


View larger version (13K):

[in a new window]
  		Fig. 3. —Graph shows change in mean glucose metabolism, or maximum standardized uptake value (SUVmax,) on FDG PET images in 29 patients. Decrease in mean SUVmax 2 months after treatment was significant (p < 0.0001, Student's t test; p < 0.0001, Wilcoxon's signed rank test).

 


View larger version (14K):

[in a new window]
  		Fig. 4. —Graph shows change in mean tumor density in Hounsfield units in 29 patients. Decrease in mean Hounsfield units 2 months after treatment was significant (p < 0.0025, Student's t test; p < 0.0011, Wilcoxon's signed rank test).

 


View larger version (132K):

[in a new window]
  		Fig. 5A. —51-year-old man with primary gastrointestinal stromal tumor in colon and recurrent disease with peritoneal metastases. Pretreatment CT scan (A) shows peritoneal mass (arrows, A) with relatively low density (42 H) corresponding to lesion with markedly increased glucose uptake (arrows, B) on FDG PET scan (B).

 


View larger version (91K):

[in a new window]
  		Fig. 5B. —51-year-old man with primary gastrointestinal stromal tumor in colon and recurrent disease with peritoneal metastases. Pretreatment CT scan (A) shows peritoneal mass (arrows, A) with relatively low density (42 H) corresponding to lesion with markedly increased glucose uptake (arrows, B) on FDG PET scan (B).

 


View larger version (136K):

[in a new window]
  		Fig. 5C. —51-year-old man with primary gastrointestinal stromal tumor in colon and recurrent disease with peritoneal metastases. and D, CT scan (C) obtained 2 months after treatment shows that mass has become larger (arrows, C). CT density (30 H), however, had decreased with no appreciable glucose uptake (arrows, D) seen on FDG PET scan (D), corresponding to clinical improvement.

 


View larger version (100K):

[in a new window]
  		Fig. 5D. —51-year-old man with primary gastrointestinal stromal tumor in colon and recurrent disease with peritoneal metastases. CT scan (C) obtained 2 months after treatment shows that mass has become larger (arrows, C). CT density (30 H), however, had decreased with no appreciable glucose uptake (arrows, D) seen on FDG PET scan (D), corresponding to clinical improvement.

 


View larger version (158K):

[in a new window]
  		Fig. 6A. —45-year-old man with recurrent gastrointestinal stromal tumor of small-bowel mesentery and hepatic metastasis. Pretreatment CT scan (A) shows hyperdense (87 H) mesenteric mass (arrows, A) in region of previous surgery corresponding to lesion with markedly increased glucose uptake (arrows, B) on FDG PET scan (B).

 


View larger version (90K):

[in a new window]
  		Fig. 6B. —45-year-old man with recurrent gastrointestinal stromal tumor of small-bowel mesentery and hepatic metastasis. Pretreatment CT scan (A) shows hyperdense (87 H) mesenteric mass (arrows, A) in region of previous surgery corresponding to lesion with markedly increased glucose uptake (arrows, B) on FDG PET scan (B).

 


View larger version (154K):

[in a new window]
  		Fig. 6C. —45-year-old man with recurrent gastrointestinal stromal tumor of small-bowel mesentery and hepatic metastasis. CT scan obtained 2 months after treatment shows that mass (arrows) has significantly decreased in both density (29 H) and size.

 


View larger version (76K):

[in a new window]
  		Fig. 6D. —45-year-old man with recurrent gastrointestinal stromal tumor of small-bowel mesentery and hepatic metastasis. FDG PET scan obtained 2 months after treatment shows no appreciable glucose uptake (arrows). On images obtained 4 months after treatment (not shown), mass had further decreased in size and density and has since remained stable.

 


View larger version (155K):

[in a new window]
  		Fig. 6E. —45-year-old man with recurrent gastrointestinal stromal tumor of small-bowel mesentery and hepatic metastasis. Photomicrograph of mesenteric mass resected at 7 months after treatment shows gross replacement of tumor by myxoid degeneration (light pink) with only microscopic viable tumor (arrows). (H and E, x40)

 


View larger version (123K):

[in a new window]
  		Fig. 7A. —68-year-old man with primary gastrointestinal stromal tumor of stomach and recurrent disease with hepatic and peritoneal metastases. Pretreatment CT scan shows large mesenteric and hepatic masses on late arterial phase image, with hyperdense tumor nodules (arrows) along periphery. Notice multiple prominent tumor vessels (arrowheads).

 


View larger version (121K):

[in a new window]
  		Fig. 7B. —68-year-old man with primary gastrointestinal stromal tumor of stomach and recurrent disease with hepatic and peritoneal metastases. CT scan obtained 2 months after treatment shows that lesions (arrows) have become significantly hypodense, and peripheral tumor nodules and tumor vessels are no longer detectable.

 


View larger version (146K):

[in a new window]
  		Fig. 8A. —56-year-old man with newly diagnosed gastrointestinal stromal tumor of jejunum with hepatic and peritoneal metastases. Pretreatment CT scan shows multiple diffuse (arrowhead) or rim-enhancing (arrows) lesions.

 


View larger version (82K):

[in a new window]
  		Fig. 8B. —56-year-old man with newly diagnosed gastrointestinal stromal tumor of jejunum with hepatic and peritoneal metastases. FDG PET scan obtained 3 days after A shows no appreciable glucose uptake.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Roentgen Ray Society.